864 related articles for article (PubMed ID: 10411544)
1. Safety and antitumor activity of recombinant soluble Apo2 ligand.
Ashkenazi A; Pai RC; Fong S; Leung S; Lawrence DA; Marsters SA; Blackie C; Chang L; McMurtrey AE; Hebert A; DeForge L; Koumenis IL; Lewis D; Harris L; Bussiere J; Koeppen H; Shahrokh Z; Schwall RH
J Clin Invest; 1999 Jul; 104(2):155-62. PubMed ID: 10411544
[TBL] [Abstract][Full Text] [Related]
2. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
3. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
5. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice.
Xiang H; Nguyen CB; Kelley SK; Dybdal N; Escandón E
Drug Metab Dispos; 2004 Nov; 32(11):1230-8. PubMed ID: 15282212
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
[TBL] [Abstract][Full Text] [Related]
7. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
Pollack IF; Erff M; Ashkenazi A
Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
9. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.
Roth W; Isenmann S; Naumann U; Kügler S; Bähr M; Dichgans J; Ashkenazi A; Weller M
Biochem Biophys Res Commun; 1999 Nov; 265(2):479-83. PubMed ID: 10558893
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
11. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.
Mace TA; Yamane N; Cheng J; Hylander BL; Repasky EA
Immunol Invest; 2006; 35(3-4):279-96. PubMed ID: 16916755
[TBL] [Abstract][Full Text] [Related]
12. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
13. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
14. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
15. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
Fulda S; Wick W; Weller M; Debatin KM
Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245
[TBL] [Abstract][Full Text] [Related]
16. Expression and antitumor effects of TRAIL in human cholangiocarcinoma.
Tanaka S; Sugimachi K; Shirabe K; Shimada M; Wands JR
Hepatology; 2000 Sep; 32(3):523-7. PubMed ID: 10960444
[TBL] [Abstract][Full Text] [Related]
17. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo.
Weber T; Lu M; Andera L; Lahm H; Gellert N; Fariss MW; Korinek V; Sattler W; Ucker DS; Terman A; Schröder A; Erl W; Brunk UT; Coffey RJ; Weber C; Neuzil J
Clin Cancer Res; 2002 Mar; 8(3):863-9. PubMed ID: 11895920
[TBL] [Abstract][Full Text] [Related]
19. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
20. Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK; Ashkenazi A
Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
